Mariola A. Vazquez-Martinez

Hematology Oncology | Hematology | Oncology

715 Ave Ponce De Leon
Stop 37.5
San Juan, PR 00917

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.

Journal: American journal of hematology

Published: July 30, 2025

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

Journal: Blood cancer journal

Published: June 30, 2025

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Journal: Blood

Published: May 05, 2025

Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.

Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.

Journal: Blood advances

Published: February 03, 2025

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Journal: Blood cancer journal

Published: December 27, 2024

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Journal: Blood cancer discovery

Published: December 24, 2024

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Journal: Blood cancer journal

Published: December 24, 2024

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.

Journal: Blood cancer journal

Published: August 23, 2024

New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches.

New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches.

Journal: Cancers

Published: January 15, 2024

From the Nares to the Bone Marrow: A Role for Transarterial Embolization in an Aberrant Life-Threatening Cause of Epistaxis.

From the Nares to the Bone Marrow: A Role for Transarterial Embolization in an Aberrant Life-Threatening Cause of Epistaxis.

Journal: Cureus

Published: November 09, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026